FXYD3 Antibody

What is FXYD3 and why is it significant in research?

FXYD3 (also known as Mat-8 or PLML) is a single-span membrane protein belonging to the FXYD family of ion transport regulators. It plays a crucial role in maintaining sodium and potassium gradients across cell membranes by regulating the sodium/potassium-transporting ATPase (Na+/K+ ATPase) . This regulation is essential for processes including renal sodium reabsorption, muscle contraction, and neuronal excitability . FXYD3 is characterized by a 35 amino acid signature domain starting with the sequence PFXYD and containing seven invariant and six conserved amino acids . The protein is notably expressed in certain cancer types, particularly a subset of human breast tumors, suggesting its importance in cancer biology . Recent research has demonstrated FXYD3's role in facilitating Na+ and liquid absorption across human airway epithelia, further expanding its physiological significance .

How do FXYD3 isoforms differ structurally and functionally?

FXYD3 exists in multiple isoforms resulting from alternative splicing:

The long versus short FXYD3 mRNA transcripts can be evaluated using RT-PCR with primers designed to common nucleotides that flank the 78-bp deletion in the short FXYD3, yielding either 97-bp (short) or 175-bp (long) PCR products . This structural variation results in different regulatory effects on ion transport and may have implications for cellular function in normal and pathological conditions.

What are the key characteristics of available FXYD3 antibodies?

Various FXYD3 antibodies are available for research, each with specific properties:

When selecting an antibody, researchers should consider the specific application requirements, target species, and the region of FXYD3 being studied .

How should FXYD3 antibodies be optimized for immunofluorescence studies?

For optimal immunofluorescence detection of FXYD3:

• Cell/tissue preparation:

  • Fix specimens with 4% paraformaldehyde

  • Permeabilize with 0.2% Triton X-100

  • Block nonspecific binding with appropriate blocking buffer (e.g., Superblock)

• Antibody incubation protocol:

  • Primary antibody: Use anti-FXYD3 at optimal dilution (e.g., 1:50 for rabbit anti-FXYD3)

  • For co-localization studies, include antibodies against interacting partners (e.g., 1:1000 mouse anti-ATP1A1)

  • Include appropriate controls (e.g., phalloidin for actin cytoskeleton visualization)

  • Incubate overnight at 4°C

  • Wash thoroughly

  • Incubate with appropriate secondary antibodies (e.g., goat anti-rabbit-Alexa-568 at 1:1000) for 1 hour at room temperature protected from light

• Imaging considerations:

  • FXYD3 typically shows membrane localization, particularly co-localizing with Na+/K+ ATPase

  • In some cancer cells, additional perinuclear distribution may be observed

  • Use appropriate controls to distinguish specific from nonspecific staining

What are the critical parameters for successful FXYD3 Western blotting?

Western blotting for FXYD3 requires careful attention to several parameters:

• Sample preparation:

  • Use appropriate lysis buffers that effectively solubilize membrane proteins

  • Include protease inhibitors to prevent degradation of this small protein

• Gel selection and running conditions:

  • FXYD3 is a small protein (~8-9 kDa), requiring higher percentage gels (12-15%)

  • Consider using Tricine-SDS-PAGE for better resolution of small proteins

• Antibody selection and dilution:

  • Recommended dilutions vary by antibody (e.g., 1:500-1:2000 for polyclonal antibody 15853-1-AP)

  • Include appropriate positive controls (e.g., COLO 320 cells, A375 cells, SGC-7901 cells have been verified to express FXYD3)

• Detection considerations:

  • Expected molecular weight is approximately 8-9 kDa

  • Multiple bands may indicate different isoforms, post-translational modifications, or degradation products

  • Verify specificity with FXYD3 knockdown experiments

How can siRNA be effectively used to study FXYD3 function?

siRNA approaches provide valuable insights into FXYD3 function:

• Validated siRNA options:

  • Human siRNA against FXYD3 (pools of three to five target-specific 19-25 nt siRNAs) has been successfully used

  • Always include non-silencing control siRNA

• Transfection protocol optimization:

  • Follow manufacturer's instructions for cell-specific transfection conditions

  • Verify knockdown efficiency by both RT-PCR and Western blotting

  • Optimal assessment timepoint is typically 48-72 hours post-transfection

• Functional readouts after FXYD3 knockdown:

  • Electrophysiological measurements: Ouabain-sensitive short-circuit currents decrease after FXYD3 knockdown

  • Amiloride-sensitive short-circuit currents: Reduced after FXYD3 knockdown

  • Liquid absorption: Diminished across intact epithelia following FXYD3 knockdown

  • Chemosensitivity: Increased sensitivity to doxorubicin in cancer cells with high FXYD3 expression

How can researchers investigate FXYD3-Na+/K+ ATPase interactions?

Investigating the interaction between FXYD3 and Na+/K+ ATPase requires specialized approaches:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate with anti-FXYD3 antibody and probe for α1 Na+/K+ ATPase subunit

  • Alternatively, immunoprecipitate with anti-α1 subunit antibody and probe for FXYD3

  • Approximate binding efficiency between FXYD3 and α1 subunit can reach ~90% in cells with high expression

• Displacement studies:

  • FXYD3 peptide derivatives (e.g., FXYD3-pep SKSK) can displace native FXYD3 from α1 Na+/K+ ATPase

  • This displacement can be quantified by Co-IP before and after peptide treatment

  • Incubation with 1 μM FXYD3-pep SKSK for 2 hours has been shown to effectively disrupt this interaction

• Functional consequences of interaction:

  • FXYD3 increases transport capacity of Na+/K+ ATPase

  • FXYD3 reduces glutathionylation of the Na+/K+ ATPase β1 subunit (ATP1B1)

  • This protection against glutathionylation prevents inhibition of ATP1B1 activity

What approaches can be used to study FXYD3's role in cancer?

FXYD3's importance in cancer research requires specialized methodologies:

• Expression profiling in cancer tissues:

  • FXYD3 is notably overexpressed in certain cancers, including breast and pancreatic cancer

  • Immunohistochemistry using validated FXYD3 antibodies can detect expression patterns

  • Recommended antigen retrieval: TE buffer pH 9.0 or citrate buffer pH 6.0

• Cancer stem cell (CSC) investigations:

  • FXYD3 functionally demarcates a breast cancer stem cell population

  • FXYD3 knockdown significantly decreases spheroid-forming ability in vitro and tumor-initiating ability in vivo

  • FXYD3-high cells among NRP1-high or IGF1R-high CSCs appear to represent quiescent ancestor-like CSCs

• Treatment resistance studies:

  • Suppression of FXYD3 with siRNA increases sensitivity to doxorubicin in FXYD3-overexpressing cancer cells

  • FXYD3 peptide derivatives can modulate chemosensitivity:

    • FXYD3-pep SKSK (with Cys mutated to Ser) increases doxorubicin cytotoxicity

    • FXYD3-pep CKCK (retaining Cys residues) enhances protection against doxorubicin

How can FXYD3 peptide derivatives be utilized as research tools?

FXYD3 peptide derivatives offer powerful tools for investigating FXYD3 function:

• Design considerations:

  • FXYD3-pep CKCK: Retains cysteine residues critical for protecting β1 subunit against glutathionylation

  • FXYD3-pep SKSK: Contains cysteine-to-serine mutations, disrupting this protective function

• Visualization strategies:

  • Fluorescent tagging (e.g., TRITC) allows tracking of cellular uptake and distribution

  • TRITC-labeled FXYD3-pep SKSK shows predominantly perinuclear distribution in cells expressing FXYD3

• Functional applications:

  • Displacement of native FXYD3 from Na+/K+ ATPase complexes

  • Modulation of treatment sensitivity in cancer cells

  • Probing structural requirements for FXYD3 function through systematic amino acid substitutions

How can researchers validate FXYD3 antibody specificity?

Validating FXYD3 antibody specificity is crucial for reliable results:

• Genetic validation approaches:

  • siRNA-mediated knockdown should reduce or eliminate signal

  • Comparison across multiple cell lines with varying FXYD3 expression levels

  • Testing in tissues known to express or lack FXYD3

• Molecular weight verification:

  • Expected molecular weight: 8-9 kDa (calculated MW: 9 kDa)

  • FXYD3 is a 67 amino acid protein with a putative 20 amino acid leader sequence

• Cross-reactivity assessment:

  • Test for potential cross-reactivity with other FXYD family members

  • Check reactivity across species if working with non-human models (sequence homology: Mouse - 37%, Rat - 35%)

What factors influence FXYD3 expression and how might they affect experimental outcomes?

Several factors influence FXYD3 expression that may impact experimental results:

• Tissue-specific expression patterns:

  • FXYD3 is expressed in specific tissues, including a subset of breast tumors

  • Expression levels vary significantly across different cancer cell lines

• Regulatory mechanisms:

  • TGF-β signaling negatively regulates FXYD3 expression through the transcription factor ZEB/dEF1

  • Expression may be altered by various physiological and pathological conditions

• Experimental considerations:

  • Cell culture conditions may affect FXYD3 expression levels

  • FXYD3 expression appears higher in Ki67-negative cells compared to Ki67-positive cells within certain populations, suggesting cell cycle dependence

  • Treatment with oxidative stress inducers (e.g., doxorubicin) may alter FXYD3 function

What are the critical controls for studies involving FXYD3 antibodies?

Essential controls for FXYD3 antibody studies include:

• Positive controls:

  • Cell lines verified to express FXYD3 (e.g., COLO 320, A375, SGC-7901 cells)

  • Tissue samples with known FXYD3 expression (e.g., human breast cancer tissue, human pancreas cancer tissue)

• Negative controls:

  • Cell lines with low or no FXYD3 expression

  • Non-immune IgG controls for immunoprecipitation experiments

  • Secondary antibody-only controls for immunofluorescence

• Validation controls:

  • siRNA knockdown samples to confirm antibody specificity

  • Peptide competition assays where appropriate

  • Multiple antibodies targeting different epitopes for confirmation

How is FXYD3 being studied in airway epithelial function?

Recent research reveals FXYD3's role in airway epithelial function:

• Sodium and liquid absorption:

  • FXYD3 facilitates Na+ and liquid absorption across human airway epithelia

  • This occurs through increasing the transport capacity of the Na+/K+ ATPase

  • FXYD3 knockdown reduces amiloride-sensitive short-circuit currents and liquid absorption

• Experimental approaches:

  • Permeabilizing apical membranes with nystatin allows measurement of ouabain-sensitive short-circuit currents

  • Comparing these currents between control and FXYD3-knockdown epithelia quantifies FXYD3's contribution

  • These findings have implications for understanding airway diseases involving fluid balance dysregulation

What therapeutic applications are emerging from FXYD3 research?

FXYD3 research is revealing potential therapeutic applications:

• Cancer treatment sensitization:

  • FXYD3-pep SKSK reproduces the increase in doxorubicin-induced cytotoxicity seen with FXYD3 siRNA

  • This effect is specific to cancer cells that overexpress FXYD3, not affecting cells with low expression

  • The mechanism involves disruption of FXYD3's protective effects against oxidative stress

• Respiratory disorder treatment:

  • FXYD3-pep CKCK, which retains the cysteine residue important for Na+/K+ ATPase function, may have therapeutic potential

  • Potential applications include acute respiratory distress syndromes, including those caused by infections

  • The peptide could help maintain Na+ export from alveolar cells and preserve epithelial barrier integrity

How are advanced molecular techniques enhancing FXYD3 research?

Cutting-edge techniques are advancing FXYD3 research:

• Single-cell RNA sequencing:

  • Enables analysis of FXYD3 expression in heterogeneous cell populations

  • Has revealed that FXYD3-high cells within cancer stem cell populations represent quiescent ancestor-like cells

  • Allows correlation of FXYD3 expression with other stemness markers like ALDH1A3 and CD44

• Peptide engineering:

  • Custom-designed FXYD3 peptide derivatives with specific modifications (e.g., FXYD3-pep CKCK vs. FXYD3-pep SKSK)

  • Fluorescent tagging for visualization (e.g., TRITC-tagged peptides)

  • These tools allow rapid elimination or amplification of native FXYD3 function

• Glutathionylation studies:

  • Assessing FXYD3 glutathionylation through disulfide exchange with oxidized glutathione (GSSG)

  • Evaluating the role of specific cysteine residues in protecting against β1 subunit glutathionylation

  • These studies provide insights into FXYD3's molecular mechanism in protecting cells against oxidative stress